HOUSTON, Jan. 5, 2018 /PRNewswire/ -- RadiaDyne announces issuance of US Patent 9,833,637, a skin patch dosimeter, which relates to the monitoring of skin radiation dose delivered during cancer treatment. "This issuance of this patent provides broad protection for our unique sensor delivery devices for skin applications related to the OARtrac® patient radiation dose monitoring platform, and continues to build on our robust IP portfolio," said John Isham, RadiaDyne's founder. "We are pleased with the issuance of claims for this submission and look forward to submitting additional applications as RadiaDyne continues to develop new clinical devices for their OARtrac® system," said Tamsen Valoir, RadiaDyne's legal counsel at Boulware & Valoir. "We are excited Radiation Oncologists can now routinely monitor skin radiation dose for many types of cancer treatments in real-time, which is vital for the best possible clinical results," said Bret Boudousquie, RadiaDyne's President.
OARtrac® is the first of its kind patient dose monitoring platform which provides gold standard accuracy, real-time pinpoint measurement, and proprietary intracavitary delivery devices to measure physical dose during radiation treatment. OARtrac® provides critical radiation dose feedback which helps facilitate adaptive radiotherapy with the goal to reduce side effects and offer better clinical outcomes.>
RadiaDyne is a privately held diagnostic and medical device company focused on patient dose monitoring technology to improve cancer treatment outcomes. RadiaDyne designs and innovates specialized sensor technology and medical treatment devices which assist Radiation Oncologists in delivering radiation dose to the cancerous targets, while minimizing damage to the surrounding healthy tissue.